MEMPHASYS LIMITED. — Capital/Financing Update 2013

Aug 1, 2013

==> picture [197 x 25] intentionally omitted <==

==> picture [197 x 25] intentionally omitted <==

==> picture [197 x 25] intentionally omitted <==

==> picture [197 x 24] intentionally omitted <==

FOR IMMEDIATE RELEASE

NuSep SPP Update & Investor Meetings

Sydney, Australia 2[nd] August 2013 – NuSep (ASX:NSP) wishes to advise the market that the $1.8m Share Purchase Plan (SPP) announced last week will close on Monday 19[th] August 2013 . The SPP documentation was mailed to shareholders on 31[st] July 2013.

In order to provide NuSep shareholders with additional information on the Company’s activities the Company will hold the following investor presentations:

Date & Time	**Location **
Thursday 8thAugust 2013 at 12pm	Melbourne- c/- HWL, Level 26, 530 Collins Street, Melbourne
Friday 9thAugust 2013 at 12pm	Sydney - c/- HWL, Level 14, Australia Square 264-278 GeorgeStreet, Sydney

All shareholders are invited to attend these presentations. Please contact Na Li at NuSep on (02) 84157300 or email to cosec@nusep.com if you wish to attend these presentations.

-END-

For more information please contact:

Contact: Prakash Patel Managing Director +61 2 8415 7300

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques based on its PrIME[1] technology. The PrIME technology has produced a number of world firsts including the world’s first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep’s world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

1 PrIME stands for Pr eparative I solation by M embrane E lectrophoresis

NuSep Holdings Ltd Postal Address Contact Details Email info@nusep.com 30 Richmond Rd P.O. Box 2202 Telephone +61 2 8415 7300 Web www.nusep.com Homebush NSW 2140 Homebush West NSW 2140 Facsimile +61 2 8415 7399 ABN 33 120 047 556

– 2 –

==> picture [12 x 17] intentionally omitted <==

• Gels – NuSep manufactures and sells precast gels including the innovative nUView Gels, which can be visualised 2 minutes after use.

==> picture [12 x 17] intentionally omitted <==

• Separation Instruments – NuSep has developed two unique biological separation instruments. The ProteomeSep can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF.

==> picture [12 x 17] intentionally omitted <==

• Biological Products – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin .

For more information about NuSep please visit the company’s website www.NuSep.com

About PrIME Biologics Pte Ltd

PrIME Biologics is a Singapore based biotech company that has developed a disposable therapeutic plasma manufacturing process based on NuSep’s PrIME Technology. NuSep has a 90% shareholding in PrIME Biologics. PrIME Biologics process is based on the Pr eparative I solation by M embrane E lectrophoresis (PrIME) technology developed by NuSep. PrIME provides disposable modular processing that is ‘electronically’ driven membrane fractionation.

The PrIME process increases product yields to over 90% relative to the existing process 50% while increasing product safety. The PrIME has been shown to remove virus, bacteria, endotoxins and prions which cause ‘Mad Cow Disease’. Further, PrIME Biologics process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.

The initial application for the PrIME process will be the Currently Unprocessable Plasma which represents approximately 50% of all the plasma collected in many Asian countries.